1
|
Jian X, Chen J, Ding S, Garofalo A, Gong X, Holland C, Huang J, Chan VS, Qin X, Yu G, Ma RR, Du X, Hong R, Staebler G, Wang H, Yan Z, Bass E, Brower D, Ding W, Orlov D. Experimental Validation of a Kinetic Ballooning Mode in High-Performance High-Bootstrap Current Fraction Fusion Plasmas. Phys Rev Lett 2023; 131:145101. [PMID: 37862644 DOI: 10.1103/physrevlett.131.145101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 07/09/2023] [Accepted: 08/21/2023] [Indexed: 10/22/2023]
Abstract
We report the observation of a set of coherent high frequency electromagnetic fluctuations that leads to a turbulence induced self-regulating phenomenon in the DIII-D high bootstrap current fraction plasma. The fluctuations have frequency of 130-220 kHz, the poloidal wavelength and phase velocity are 16-30 m^{-1} and ∼30 km/s, respectively, in the outboard midplane with the estimated toroidal mode number n∼5-9. The fluctuations are located in the internal transport barrier (ITB) region at large radius and are experimentally validated to be kinetic ballooning modes (KBM). Quasilinear estimation predicts the KBM to be able to drive experimental particle flux and non-negligible thermal flux, suggesting its significant role in regulating the ITB saturation.
Collapse
Affiliation(s)
- X Jian
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei, Anhui 230031, China
- University of California, San Diego, La Jolla, California 92093-0417, USA
| | - J Chen
- University of California Los Angeles, Los Angeles, California 90095, USA
| | - S Ding
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - A Garofalo
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - X Gong
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei, Anhui 230031, China
| | - C Holland
- University of California, San Diego, La Jolla, California 92093-0417, USA
| | - J Huang
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei, Anhui 230031, China
| | - V S Chan
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - X Qin
- University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - G Yu
- University of California at Davis, Davis, California 95616, USA
| | - R R Ma
- Southwestern Institute of Physics, P.O. Box 432 Chengdu 610041, China
| | - X Du
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - R Hong
- University of California Los Angeles, Los Angeles, California 90095, USA
| | - G Staebler
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - H Wang
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608, USA
| | - Z Yan
- University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - E Bass
- University of California, San Diego, La Jolla, California 92093-0417, USA
| | - D Brower
- University of California Los Angeles, Los Angeles, California 90095, USA
| | - W Ding
- University of California Los Angeles, Los Angeles, California 90095, USA
| | - D Orlov
- University of California, San Diego, La Jolla, California 92093-0417, USA
| |
Collapse
|
2
|
Fratelli N, Prefumo F, Maggi C, Cavalli C, Sciarrone A, Garofalo A, Viora E, Vergani P, Ornaghi S, Betti M, Vaglio Tessitore I, Cavaliere AF, Buongiorno S, Vidiri A, Fabbri E, Ferrazzi E, Maggi V, Cetin I, Frusca T, Ghi T, Kaihura C, Di Pasquo E, Stampalija T, Belcaro C, Quadrifoglio M, Veneziano M, Mecacci F, Simeone S, Locatelli A, Consonni S, Chianchiano N, Labate F, Cromi A, Bertucci E, Facchinetti F, Fichera A, Granata D, D'Antonio F, Foti F, Avagliano L, Bulfamante G, Calì G. Third-trimester ultrasound for antenatal diagnosis of placenta accreta spectrum in women with placenta previa: results from the ADoPAD study. Ultrasound Obstet Gynecol 2022; 60:381-389. [PMID: 35247287 PMCID: PMC9544821 DOI: 10.1002/uog.24889] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 01/27/2022] [Accepted: 03/05/2022] [Indexed: 06/01/2023]
Abstract
OBJECTIVE To evaluate the performance of third-trimester ultrasound for the diagnosis of clinically significant placenta accreta spectrum disorder (PAS) in women with low-lying placenta or placenta previa. METHODS This was a prospective multicenter study of pregnant women aged ≥ 18 years who were diagnosed with low-lying placenta (< 20 mm from the internal cervical os) or placenta previa (covering the internal cervical os) on ultrasound at ≥ 26 + 0 weeks' gestation, between October 2014 and January 2019. Ultrasound suspicion of PAS was raised in the presence of at least one of these signs on grayscale ultrasound: (1) obliteration of the hypoechogenic space between the uterus and the placenta; (2) interruption of the hyperechogenic interface between the uterine serosa and the bladder wall; (3) abnormal placental lacunae. Histopathological examinations were performed according to a predefined protocol, with pathologists blinded to the ultrasound findings. To assess the ability of ultrasound to detect clinically significant PAS, a composite outcome comprising the need for active management at delivery and histopathological confirmation of PAS was considered the reference standard. PAS was considered to be clinically significant if, in addition to histological confirmation, at least one of these procedures was carried out after delivery: use of hemostatic intrauterine balloon, compressive uterine suture, peripartum hysterectomy, uterine/hypogastric artery ligation or uterine artery embolization. The diagnostic performance of each ultrasound sign for clinically significant PAS was evaluated in all women and in the subgroup who had at least one previous Cesarean section and anterior placenta. Post-test probability was assessed using Fagan nomograms. RESULTS A total of 568 women underwent transabdominal and transvaginal ultrasound examinations during the study period. Of these, 95 delivered in local hospitals, and placental pathology according to the study protocol was therefore not available. Among the 473 women for whom placental pathology was available, clinically significant PAS was diagnosed in 99 (21%), comprising 36 cases of placenta accreta, 19 of placenta increta and 44 of placenta percreta. The median gestational age at the time of ultrasound assessment was 31.4 (interquartile range, 28.6-34.4) weeks. A normal hypoechogenic space between the uterus and the placenta reduced the post-test probability of clinically significant PAS from 21% to 5% in women with low-lying placenta or placenta previa in the third trimester of pregnancy and from 62% to 9% in the subgroup with previous Cesarean section and anterior placenta. The absence of placental lacunae reduced the post-test probability of clinically significant PAS from 21% to 9% in women with low-lying placenta or placenta previa in the third trimester of pregnancy and from 62% to 36% in the subgroup with previous Cesarean section and anterior placenta. When abnormal placental lacunae were seen on ultrasound, the post-test probability of clinically significant PAS increased from 21% to 59% in the whole cohort and from 62% to 78% in the subgroup with previous Cesarean section and anterior placenta. An interrupted hyperechogenic interface between the uterine serosa and bladder wall increased the post-test probability for clinically significant PAS from 21% to 85% in women with low-lying placenta or placenta previa and from 62% to 88% in the subgroup with previous Cesarean section and anterior placenta. When all three sonographic markers were present, the post-test probability for clinically significant PAS increased from 21% to 89% in the whole cohort and from 62% to 92% in the subgroup with previous Cesarean section and anterior placenta. CONCLUSIONS Grayscale ultrasound has good diagnostic performance to identify pregnancies at low risk of PAS in a high-risk population of women with low-lying placenta or placenta previa. Ultrasound may be safely used to guide management decisions and concentrate resources on patients with higher risk of clinically significant PAS. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- N. Fratelli
- Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental SciencesUniversity of BresciaBresciaItaly
| | - F. Prefumo
- Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental SciencesUniversity of BresciaBresciaItaly
| | - C. Maggi
- Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental SciencesUniversity of BresciaBresciaItaly
| | - C. Cavalli
- Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental SciencesUniversity of BresciaBresciaItaly
| | - A. Sciarrone
- Obstetrics–Gynecological Ultrasound and Prenatal Diagnosis Unit, Department of Obstetrics and GynecologyCittà della Salute e della ScienzaTurinItaly
| | - A. Garofalo
- Obstetrics–Gynecological Ultrasound and Prenatal Diagnosis Unit, Department of Obstetrics and GynecologyCittà della Salute e della ScienzaTurinItaly
| | - E. Viora
- Obstetrics–Gynecological Ultrasound and Prenatal Diagnosis Unit, Department of Obstetrics and GynecologyCittà della Salute e della ScienzaTurinItaly
| | - P. Vergani
- University of Milan‐Bicocca, School of Medicine and Surgery, Department of Obstetrics and GynecologyFondazione MBBM Onlus, San Gerardo HospitalMonzaItaly
| | - S. Ornaghi
- University of Milan‐Bicocca, School of Medicine and Surgery, Department of Obstetrics and GynecologyFondazione MBBM Onlus, San Gerardo HospitalMonzaItaly
| | - M. Betti
- Obstetrics and Gynaecology Unit, A. Manzoni Hospital, ASST LeccoLeccoItaly
| | - I. Vaglio Tessitore
- University of Milan‐Bicocca, School of Medicine and Surgery, Department of Obstetrics and GynecologyFondazione MBBM Onlus, San Gerardo HospitalMonzaItaly
| | - A. F. Cavaliere
- Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità PubblicaFondazione Policlinico Universitario ‘A. Gemelli’ IRCCS‐Università Cattolica del Sacro CuoreRomeItaly
| | - S. Buongiorno
- Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità PubblicaFondazione Policlinico Universitario ‘A. Gemelli’ IRCCS‐Università Cattolica del Sacro CuoreRomeItaly
| | - A. Vidiri
- Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità PubblicaFondazione Policlinico Universitario ‘A. Gemelli’ IRCCS‐Università Cattolica del Sacro CuoreRomeItaly
| | - E. Fabbri
- Obstetrics and Gynecology UnitBuzzi Children's Hospital, University of MilanMilanItaly
| | - E. Ferrazzi
- Fondazione IRCCS Ca Granda Ospedale Maggiore PoliclinicoMilano, Unit of ObstetricsMilanItaly
- Department of Clinical and Community SciencesUniversity of MilanMilanItaly
| | - V. Maggi
- Fondazione IRCCS Ca Granda Ospedale Maggiore PoliclinicoMilano, Unit of ObstetricsMilanItaly
| | - I. Cetin
- Obstetrics and Gynecology UnitBuzzi Children's Hospital, University of MilanMilanItaly
| | - T. Frusca
- Department of Medicine and Surgery, Obstetrics and Gynaecology UnitUniversity of ParmaParmaItaly
| | - T. Ghi
- Department of Medicine and SurgeryUniversity of ParmaParmaItaly
| | - C. Kaihura
- Department of Medicine and Surgery, Obstetrics and Gynaecology UnitUniversity of ParmaParmaItaly
| | - E. Di Pasquo
- Department of Medicine and Surgery, Obstetrics and Gynaecology UnitUniversity of ParmaParmaItaly
| | - T. Stampalija
- Unit of Fetal Medicine and Prenatal DiagnosisInstitute for Maternal and Child Health, IRCCS Burlo GarofoloTriesteItaly
- Department of Medical, Surgical and Health ScienceUniversity of TriesteTriesteItaly
| | - C. Belcaro
- Unit of Fetal Medicine and Prenatal DiagnosisInstitute for Maternal and Child Health, IRCCS Burlo GarofoloTriesteItaly
| | - M. Quadrifoglio
- Unit of Fetal Medicine and Prenatal DiagnosisInstitute for Maternal and Child Health, IRCCS Burlo GarofoloTriesteItaly
| | - M. Veneziano
- Obstetrics and Gynecology UnitBolzano HospitalBolzanoItaly
| | - F. Mecacci
- Department of Woman and Child's HealthCareggi University HospitalFlorenceItaly
| | - S. Simeone
- Department of Woman and Child's HealthCareggi University HospitalFlorenceItaly
| | - A. Locatelli
- University of Milan‐Bicocca, School of Medicine and Surgery, Obstetrics and Gynecology Unit, Carate Brianza Hospital, ASST BrianzaCarate BrianzaItaly
| | - S. Consonni
- Obstetrics and Gynecology Unit, Carate Brianza Hospital, ASST BrianzaCarate BrianzaItaly
| | - N. Chianchiano
- Fetal Medicine Unit, Bucchieri La Ferla–Fatebenefratelli HospitalPalermoItaly
| | - F. Labate
- Department of Obstetrics and GynaecologyAzienda Ospedaliera Villa Sofia CervelloPalermoItaly
| | - A. Cromi
- Department of Medicine and SurgeryUniversity of InsubriaVareseItaly
| | - E. Bertucci
- Obstetrics and Gynecology Unit, Department of Medical and Surgical Sciences for Children and AdultsUniversity of Modena and Reggio Emilia School of MedicineModenaItaly
| | - F. Facchinetti
- Obstetrics and Gynecology Unit, Department of Medical and Surgical Sciences for Children and AdultsUniversity of Modena and Reggio Emilia School of MedicineModenaItaly
| | - A. Fichera
- Division of Obstetrics and Gynecology, ASST Spedali Civili, Department of Clinical and Experimental SciencesUniversity of BresciaBresciaItaly
| | - D. Granata
- Obstetrics and Gynecology UnitBolognini HospitalSeriateItaly
| | - F. D'Antonio
- Center for Fetal Care and High‐Risk Pregnancy, Department of Obstetrics and GynecologyUniversity of ChietiChietiItaly
| | - F. Foti
- Obstetrics and Gynecology Unit, Civico Hospital of PartinicoPalermoItaly
| | - L. Avagliano
- Department of Health SciencesUniversità degli Studi di MilanoMilanItaly
| | - G. P. Bulfamante
- Department of Health SciencesUniversità degli Studi di MilanoMilanItaly
| | - G. Calì
- Department of Obstetrics and GynaecologyArnas Civico HospitalPalermoItaly
| | | |
Collapse
|
3
|
Eldon D, Wang H, Wang L, Barr J, Ding S, Garofalo A, Gong X, Guo H, Järvinen A, Li K, McClenaghan J, McLean A, Samuell C, Watkins J, Weisberg D, Yuan Q. An analysis of controlled detachment by seeding various impurity species in high performance scenarios on DIII-D and EAST. Nuclear Materials and Energy 2021. [DOI: 10.1016/j.nme.2021.100963] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Sworder B, Kurtz DM, Alig S, Frank MJ, Macauley CW, Garofalo A, Shukla N, Sahaf B, Esfahani MS, Sheybani N, Schroers-Martin J, Liu CL, Olsen M, Spiegel JY, Oak J, Jin MC, Beygi S, Khodadoust MS, Natkunam Y, Majzner R, Mackall CL, Diehn M, Miklos DM, Alizadeh AA. DETERMINANTS OF RESISTANCE TO ENGINEERED T‐CELL THERAPIES TARGETING CD19 IN LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.6_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- B Sworder
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - D. M Kurtz
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - S Alig
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - M. J Frank
- Stanford University Department of Medicine, Division of Blood and Bone Marrow Transplantation Palo Alto California USA
| | - C. W Macauley
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - A Garofalo
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - N Shukla
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - B Sahaf
- Stanford University Department of Medicine, Division of Blood and Bone Marrow Transplantation Palo Alto California USA
| | - M. S Esfahani
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - N Sheybani
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - J Schroers-Martin
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - C. L Liu
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - M. Olsen
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - J. Y Spiegel
- Stanford University Department of Medicine, Division of Blood and Bone Marrow Transplantation Palo Alto California USA
| | - J Oak
- Stanford University Department of Pathology Palo Alto California USA
| | - M. C Jin
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - S Beygi
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - M. S Khodadoust
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| | - Y Natkunam
- Stanford University Department of Pathology Palo Alto California USA
| | - R Majzner
- Stanford University Department of Pediatrics Palo Alto California USA
| | - C. L Mackall
- Stanford University Department of Pediatrics Palo Alto California USA
| | - M Diehn
- Stanford University Department of Radiation Oncology Palo Alto California USA
| | - D. M Miklos
- Stanford University Department of Medicine, Division of Blood and Bone Marrow Transplantation Palo Alto California USA
| | - A. A Alizadeh
- Stanford University Department of Medicine, Division of Oncology Palo Alto California USA
| |
Collapse
|
5
|
Agovino M, Matricano D, Garofalo A. Waste management and competitiveness of firms in Europe: A stochastic frontier approach. Waste Manag 2020; 102:528-540. [PMID: 31765973 DOI: 10.1016/j.wasman.2019.11.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Revised: 09/04/2019] [Accepted: 11/17/2019] [Indexed: 06/10/2023]
Abstract
The present paper aims to investigate the relationship between achieved recycling rates and the competitiveness of firms working in circular economy sectors. The econometric analysis is based on the Stochastic Frontier Analysis (a parametric model) and is carried out in reference to seventeen European countries over the years 2010-2016. It reveals intriguing results about the positive effect that achieved recycling rates of packaging, electronic and bio-waste can exert on the competitiveness of firms, although differences emerge across the countries considered. Furthermore, through the inefficiency function, a positive effect of R&D spending on competitiveness of European firms is disclosed.
Collapse
Affiliation(s)
- M Agovino
- Department of Economic and Legal Studies, Università degli Studi di Napoli Parthenope, Via Generale Parisi, 13, 80132 Napoli (NA), Italy.
| | - D Matricano
- Department of Management, Università degli Studi della Campania "L. Vanvitelli", Corso Gran Priorato di Malta, 1, 81043 Capua (CE), Italy
| | - A Garofalo
- Department of Economic and Legal Studies, Università degli Studi di Napoli Parthenope, Via Generale Parisi, 13, 80132 Napoli (NA), Italy
| |
Collapse
|
6
|
Soo J, Schroers-Martin J, Garofalo A, Kurtz D, D'Emilio N, Luikart H, Alizadeh A, Khush K. Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
7
|
Buttery RJ, Covele B, Ferron J, Garofalo A, Holcomb CT, Leonard T, Park JM, Petrie T, Petty C, Staebler G, Strait EJ, Van Zeeland M. Correction to: DIII-D Research to Prepare for Steady State Advanced Tokamak Power Plants. J Fusion Energ 2018. [DOI: 10.1007/s10894-018-0197-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Peysson Y, Bonoli PT, Chen J, Garofalo A, Hillairet J, Li M, Qian J, Shiraiwa S, Decker J, Ding BJ, Ekedahl A, Goniche M, Zhai X. Current Challenges in the First Principle Quantitative Modelling of the Lower Hybrid Current Drive in Tokamaks. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201715702007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Iben Nasser I, Algieri C, Garofalo A, Drioli E, Ahmed C, Donato L. Hybrid imprinted membranes for selective recognition of quercetin. Sep Purif Technol 2016. [DOI: 10.1016/j.seppur.2016.03.015] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
10
|
Pilloni E, Alemanno MG, Gaglioti P, Sciarrone A, Garofalo A, Biolcati M, Botta G, Viora E, Todros T. Accuracy of ultrasound in antenatal diagnosis of placental attachment disorders. Ultrasound Obstet Gynecol 2016; 47:302-307. [PMID: 25964123 DOI: 10.1002/uog.14893] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Revised: 03/13/2015] [Accepted: 04/24/2015] [Indexed: 05/28/2023]
Abstract
OBJECTIVES To evaluate the accuracy of ultrasound in the diagnosis of placenta accreta and its variants, and to assess the impact of prenatal diagnosis in our population. METHODS A total of 314 women with placenta previa were enrolled prospectively and underwent transabdominal and transvaginal ultrasound examinations. An ultrasound diagnosis (grayscale and color/power Doppler) of placental attachment disorder (PAD) was based on the detection of at least two of the following ('two-criteria system'): loss/irregularity of the retroplacental clear zone, thinning/interruption of the uterine serosa-bladder wall interface, turbulent placental lacunae with high velocity flow, myometrial thickness < 1 mm, increased vascularity of the uterine serosa-bladder wall interface, loss of vascular arch parallel to the basal plate and/or irregular intraplacental vascularization. Definitive diagnosis was made at delivery by Cesarean section. Maternal outcome in cases diagnosed antenatally was compared with that in cases diagnosed at delivery. RESULTS There were 37/314 cases of PAD (29 anterior and eight posterior). The two-criteria system identified 30 cases of placenta accreta, providing a sensitivity of 81.1% and specificity of 98.9%. When anterior and posterior placentae were considered separately, the detection rates of PAD were 89.7 and 50.0%, respectIvely. Maternal outcome was better in women with prenatal diagnosis of PAD, as seen by less blood loss and shorter hospitalization. CONCLUSIONS Our data confirmed that grayscale and color Doppler ultrasound have good performance in the diagnosis of PAD and that prenatal diagnosis improves maternal outcome. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- E Pilloni
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - M G Alemanno
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - P Gaglioti
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - A Sciarrone
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - A Garofalo
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - M Biolcati
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - G Botta
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - E Viora
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| | - T Todros
- Department of Obstetrics and Gynecology, University of Turin, Sant' Anna Hospital, Turin, Italy
| |
Collapse
|
11
|
Barba M, Pizzuti L, Conti L, Mandoj C, Digiesi G, Antenucci A, Sergi D, Di Lauro L, Amodio A, Carpano S, Sperati F, Valle M, Garofalo A, Vizza E, Vincenzoni C, Corrado G, Maugeri-Saccà M, Vici P. The impact of fasting glucose on clinical-pathological features in epithelial ovarian cancer: results from a historic cohort. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv339.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Savarese M, Di Fruscio G, Bruno C, Torella A, Giugliano T, Mora M, Morandi L, Siciliano G, Toscano A, Garofalo A, Mongini T, Angelini C, Santoro L, Claes K, Bertini E, Santorelli F, Comi G, Sacconi S, Politano L, Nigro V. Large screening of patients diagnosed as limb girdle muscular dystrophy or congenital myopathy using Motorplex. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
13
|
Valle M, Levi Sandri GB, Carboni F, Federici O, Pizzi G, Covello R, Carpano S, Garofalo A. Limb saving procedure in metastatic leiomyosarcoma of the femoral vein: case report and literature review. Indian J Surg 2015; 77:13-5. [PMID: 25972629 DOI: 10.1007/s12262-014-1036-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Accepted: 01/08/2014] [Indexed: 10/25/2022] Open
Abstract
Primary venous leiomyosarcoma is very rare and first description was made by Perl in 1871. Most cases are from venous system and half of them are reported to originate in inferior vena cava. We report the case of a 77-year-old Caucasian man with a leiomyosarcoma of the femoral vein. A leg preservation surgery was decided. Eight months later, the patient died of tumor progression. A PubMed search using the terms "leiomyosarcoma femoral vein" and "leiomyosarcoma vein" was performed. All cases of composite iliac-femoral leiomyosarcoma were excluded, and as far as possible, only well-documented cases were included. Median age was 55 years, seven men and six women, tumor resection was performed by six authors, six others performed a vascular resection, and one preferred for a thigh excision. Prognosis remains poor if metastasis is present, and in these cases, a conservative surgery is recommended to preserve patients' quality of life.
Collapse
Affiliation(s)
- Mario Valle
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | | | - F Carboni
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - O Federici
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| | - G Pizzi
- Department of Radiology, Regina Elena National Cancer Institute, Rome, Italy
| | - R Covello
- Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy
| | - S Carpano
- Department of Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | - A Garofalo
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| |
Collapse
|
14
|
Pettini F, Ballini A, Capodiferro S, Cantore S, Cirulli N, Garofalo A, Coscia MF, De Vito D, Foti C. Management of oral pemphigus vulgaris: A case report and a clinical update. EUR J INFLAMM 2015. [DOI: 10.1177/1721727x15576854] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Pemphigus vulgaris (PV) is an uncommon autoimmune intraepithelial blistering disease. In most cases, the oral lesions were the first manifestation of the pathology. We report the case of a 42-year-old woman with a 4-month history of oral ulcerations. The patient reported that the lesions caused considerable discomfort and affected her normal oral function. On intraoral examination, ulcers were observed on the cheek and palatal mucosa and ventral surface of the tongue. No skin lesions were seen on extra oral examination. A diagnosis of PV was made after evaluating the biopsy samples. The main complication of PV is the reduced quality of life related to soreness or pain, particularly in ulcerative/erosive lesions. The presence of lesions among gingival tissues makes oral hygiene procedures very difficult, but plaque control and rigorous oral hygiene are a fundamental requisite for the treatment of any oromucosal disease.
Collapse
Affiliation(s)
- F Pettini
- Department of Interdisciplinary Medicine, University of Bari “Aldo Moro”, Bari, Italy
| | - A Ballini
- School of Medicine, University of Bari “Aldo Moro”, Bari, Italy
| | - S Capodiferro
- School of Medicine, University of Bari “Aldo Moro”, Bari, Italy
| | - S Cantore
- School of Medicine, University of Bari “Aldo Moro”, Bari, Italy
| | - N Cirulli
- School of Medicine, University of Bari “Aldo Moro”, Bari, Italy
| | - A Garofalo
- Department of Biomedical Science and Human Oncology, Section of Dermatology, University of Bari “Aldo Moro”, Bari, Italy
| | - MF Coscia
- Department of Basic Medical Science, Neurosciences and Sense Organs, Section of Microbiology, University of Bari “Aldo Moro”, Bari, Italy
| | - D De Vito
- Department of Basic Medical Science, Neurosciences and Sense Organs, Section of Microbiology, University of Bari “Aldo Moro”, Bari, Italy
| | - C Foti
- Department of Biomedical Science and Human Oncology, Section of Dermatology, University of Bari “Aldo Moro”, Bari, Italy
| |
Collapse
|
15
|
Walter A, Garofalo A, Parat A, Jouhannaud J, Pourroy G, Voirin E, Laurent S, Bonazza P, Taleb J, Billotey C, Vander Elst L, Muller RN, Begin-Colin S, Felder-Flesch D. Validation of a dendron concept to tune colloidal stability, MRI relaxivity and bioelimination of functional nanoparticles. J Mater Chem B 2015; 3:1484-1494. [DOI: 10.1039/c4tb01954g] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A dendritic coating induces colloidal stability of nanoparticles through electrostatic and steric interactions.
Collapse
|
16
|
Garofalo A, Donato L, Drioli E, Criscuoli A, Carnevale M, Alharbi O, Aljlil S, Algieri C. Supported MFI zeolite membranes by cross flow filtration for water treatment. Sep Purif Technol 2014. [DOI: 10.1016/j.seppur.2014.09.028] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Savarese M, Di Fruscio G, Torella A, Mutarelli M, Comi G, Mongini T, Ricci E, Angelini C, Fanin M, Pegoraro E, Musumeci O, Toscano A, Siciliano G, Mora M, Morandi L, Bertini E, D’Amico A, Tasca G, Bruno C, Fiorillo C, Minetti C, Santorelli F, Garofalo A, Giugliano T, Pisano C, Del Vecchio Blanco F, Piluso G, De Concilio O, Sacconi S, Politano L, Nigro V. G.O.7. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Di Fruscio G, Savarese M, Garofalo A, Mutarelli M, Nigro V. G.P.220. Neuromuscul Disord 2014. [DOI: 10.1016/j.nmd.2014.06.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
19
|
Chevallier P, Walter A, Garofalo A, Veksler I, Lagueux J, Bégin-Colin S, Felder-Flesch D, Fortin MA. Tailored biological retention and efficient clearance of pegylated ultra-small MnO nanoparticles as positive MRI contrast agents for molecular imaging. J Mater Chem B 2014; 2:1779-1790. [DOI: 10.1039/c3tb21634a] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Ultra-small MnO nanoparticles pegylated with bis-phosphonate dendrons are efficient positive MRI contrast agents. They show prolonged vascular signal enhancement, followed by efficient excretion through the hepatobiliairy and urinary pathways. This considerably decreases the potential toxicity of MnO NPs.
Collapse
Affiliation(s)
- P. Chevallier
- Centre de recherche du Centre hospitalier universitaire de Québec (CR-CHUQ)
- Axe médecine régénératrice
- Québec, Canada
- Centre de recherche sur les matériaux avancés (CERMA)
- Université Laval
| | - A. Walter
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504 CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - A. Garofalo
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504 CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - I. Veksler
- Centre de recherche du Centre hospitalier universitaire de Québec (CR-CHUQ)
- Axe médecine régénératrice
- Québec, Canada
- Centre de recherche sur les matériaux avancés (CERMA)
- Université Laval
| | - J. Lagueux
- Centre de recherche du Centre hospitalier universitaire de Québec (CR-CHUQ)
- Service d’imagerie animale (SIA)
- Québec, Canada
| | - S. Bégin-Colin
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504 CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - D. Felder-Flesch
- Institut de Physique et Chimie des Matériaux de Strasbourg (IPCMS)
- UMR 7504 CNRS-Université de Strasbourg
- 67034 Strasbourg Cedex 2, France
| | - M.-A. Fortin
- Centre de recherche du Centre hospitalier universitaire de Québec (CR-CHUQ)
- Axe médecine régénératrice
- Québec, Canada
- Centre de recherche sur les matériaux avancés (CERMA)
- Université Laval
| |
Collapse
|
20
|
Valle M, Federici O, Carboni F, Toma L, Gallo MT, Prignano G, Giannarelli D, Cenci L, Garofalo A. Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment. Eur J Surg Oncol 2013; 40:950-6. [PMID: 24246609 DOI: 10.1016/j.ejso.2013.10.015] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Revised: 10/14/2013] [Accepted: 10/19/2013] [Indexed: 12/27/2022] Open
Abstract
The incidence of infectious complications due to several contributory causes is particularly elevated and life-threatening in patients undergoing peritonectomy and HIPEC procedure for peritoneal carcinomatosis. Following a previous experience, we started a prospective protocol study of preoperative screening, perioperative prophylaxis and postoperative surveillance and treatment. A total of 111 patients with peritoneal carcinomatosis of various origin underwent CRS with HIPEC between April 2004 and December 2012. The group was divided into a pilot group of 30 patients (04/04 to 05/08) and a main group of 81 patients (06/08 to 12/12). Overall postoperative morbidity rate was 44%, with 35.8% of symptomatic infections. No post-operative mortality was observed. Microorganisms were isolated in 24 patients (80.0%) in the first group and 54 (66.7%) in the second. They were symptomatic in 18 cases (75.0%) and 25 (46.3%) cases respectively. In addition, 7 invasive candidosis were recorded (25.9%). Colon resection (P = 0.01) and duration of surgery (P = 0.0008) were associated with infection at logistic regression model. Concerning symptomatic infections, only Infection Risk Index (P = 0.009) showed significance at multivariate analysis. Despite a significant incidence of infectious complications, establishment of a prevention, surveillance and treatment protocol lead to a zero mortality rate in the observed patients of our experience. Owing to the obtained results, we suggest the use of a standardized protocol for the prevention, monitoring and treatment in all patients enrolled for cytoreductive surgery and HIPEC.
Collapse
Affiliation(s)
- M Valle
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Rome, Italy.
| | - O Federici
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Rome, Italy
| | - F Carboni
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Rome, Italy
| | - L Toma
- Department of Infectivology, Regina Elena National Cancer Institute, Rome, Italy
| | - M T Gallo
- Department of Clinical Pathology and Microbiology, Regina Elena National Cancer Institute, Rome, Italy
| | - G Prignano
- Department of Clinical Pathology and Microbiology, Regina Elena National Cancer Institute, Rome, Italy
| | - D Giannarelli
- Department of Biostatistic, Regina Elena Cancer Institute, Rome, Italy
| | - L Cenci
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Rome, Italy
| | - A Garofalo
- Department of Digestive Surgery, Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
21
|
Cenci L, Federici O, Benedetti M, Levi Sandri G, Stefanelli F, Valle M, Garofalo A. Peritonectomy and hyperthermic intraperitoneal chemotherapy in HIV patient. Eur J Surg Oncol 2013. [DOI: 10.1016/j.ejso.2013.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
22
|
Benedetti M, Carboni F, Sacconi A, Biagioni F, Garofalo A. Mir and gastric cancer: New prognostic factors. Eur J Surg Oncol 2013. [DOI: 10.1016/j.ejso.2013.07.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
23
|
|
24
|
Aiello F, Garofalo A, Aloisi AM, Lamponi S, Magnani A, Petroni A. Synthesis of esters of androgens with unsaturated fatty acids for androgen requiring therapy. J Endocrinol Invest 2013; 36:390-5. [PMID: 23095310 DOI: 10.3275/8655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Androgens' metabolism and activity are gaining a more and more important role in human physiology particularly referring to aging and to neurodegenerative diseases. Androgen treatment is often required for long-lasting disorders. In order to improve their duration and effects, androgens can be administered as esters of carboxylic acids. The novelty of our research is the use of esters of androgens with specific unsaturated fatty acids, in order to reduce possible side effects particularly related to chronic pathologies with altered lipid homeostasis such as X-linked adrenoleukodystrophy and cardiovascular disorders. Thus the esters of the main androgenic substances testosterone, dihydrotestosterone (DHT) and their metabolite 5α-androstan-3α,17β-diol were chemically obtained by coupling with different unsaturated fatty acids. To this aim, fatty acids with various degree of unsaturation and belonging to different series were selected. Specifically, oleic acid (18:1, n-9), linoleic acid (18:2, n-6), and the n-3 fatty acids, α-linolenic acid (18:3), eicosapentaenoic acid (EPA, 20:5), and docosahexaenoic acid (DHA, 22:6) were used obtaining corresponding esters with acceptable yields and good degree of purity. All the synthesized compounds were tested for their cytotoxic activities in mouse NIH3T3 and human astrocyte cell lines. The esters demonstrated good tolerability and no in vitro cytotoxic effect in both cell cultures. After these promising preliminary results, the esters will be suitable for in vivo studies in order to ascertain their pharmacokinetic characteristics and their biological effects.
Collapse
Affiliation(s)
- F Aiello
- Department of Pharmaceutical Sciences, University of Calabria, Rende (CS), Italy
| | | | | | | | | | | |
Collapse
|
25
|
Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 2012; 3:e423. [PMID: 23152059 PMCID: PMC3542596 DOI: 10.1038/cddis.2012.160] [Citation(s) in RCA: 146] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Micro RNAs (miRs) are small non-coding RNAs aberrantly expressed in human tumors. Here, we aim to identify miRs whose deregulated expression leads to the activation of oncogenic pathways in human gastric cancers (GCs). Thirty nine out of 123 tumoral and matched uninvolved peritumoral gastric specimens from three independent European subsets of patients were analyzed for the expression of 851 human miRs using Agilent Platform. The remaining 84 samples were used to validate miRs differentially expressed between tumoral and matched peritumoral specimens by qPCR. miR-204 falls into a group of eight miRs differentially expressed between tumoral and peritumoral samples. Downregulation of miR-204 has prognostic value and correlates with increased staining of Bcl-2 protein in tumoral specimens. Ectopic expression of miR-204 inhibited colony forming ability, migration and tumor engraftment of GC cells. miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment. Ectopic expression of Bcl-2 protein counteracted miR-204 pro-apoptotic activity in response to 5-fluorouracil. Altogether, these findings suggest that modulation of aberrant expression of miR-204, which in turn releases oncogenic Bcl-2 protein activity might hold promise for preventive and therapeutic strategies of GC.
Collapse
Affiliation(s)
- A Sacconi
- Translational Oncogenomic Unit, Italian National Cancer Institute Regina Elena, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Biagioni F, Sacconi A, Canu V, Mori F, Di Benedetto A, Lorenzon L, Di Agostino S, Cambria A, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G. miRNA profiling of gastric tumors unveils tumor suppressor pathway. Eur J Surg Oncol 2012. [DOI: 10.1016/j.ejso.2012.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
27
|
Savarese M, Torella A, Mutarelli M, Dionisi M, Giugliano T, Di Fruscio G, Iacomino M, Garofalo A, Aurino S, Del Vecchio Blanco F, Piluso G, Politano L, Fanin M, Angelini C, Nigro V. D.O.3 Next generation sequencing applications are ready for genetic diagnosis of muscular dystrophies. Neuromuscul Disord 2012. [DOI: 10.1016/j.nmd.2012.06.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Prater R, Buttery R, DeBoo J, Ferron J, Garofalo A, Holcomb C, Jackson G, La Haye R, Lohr J, Luce T, Petty C, Politzer P, Solomon W, Turco F. Applications of ECH on the DIII-D tokamak and projections for future ECH upgrades. EPJ Web of Conferences 2012. [DOI: 10.1051/epjconf/20123202010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Pefani E, Panoskaltsis N, Mantalaris A, Georgiadis MC, Pistikopoulos EN, Aguilar-Mahecha A, Lafleur J, Seguin C, Rosenbloom M, Przybytkowski E, Pelmus M, Diaz Z, Batist G, Basik M, Tavernier J, Brunet L, Bazot J, Chemelle M, Dalban C, Guiu S, di Martino C, Lehtio J, Branca M, Johansson H, Orre M, Granholm V, Forshed J, Perez-Bercoff M, Kall L, Nielsen KV, Andresen L, Muller S, Matthiesen S, Schonau A, Oktriani R, Wahyono A, Haryono S, Utomo A, Aryandono T, Diaz Z, Gagnon-Kugler T, Rousseau C, Aguilar-Mahecha A, Alcindor T, Aloyz R, Assouline S, Basik M, Bachvarov D, Belanger L, Camlioglu E, Cartillone M, Chabot B, Christodoulopoulos R, Courtemanche C, Constantin A, Benlimame N, Dao I, Dalfen R, Gosselin L, Habbab F, Hains M, Haliotis T, Nielsen TH, Joncas M, Kavan P, Klink R, Langlaben A, Lebel M, Lesperance B, Mann K, Masson J, Metrakos P, McNamara S, Miller WH, Orain M, Panasci L, Paquet E, Phillie M, Qureshi S, Rodrigue D, Salman A, Spatz A, Tetu B, Tosikyan A, Tsatoumas M, Vuong T, Batist G, Ruijtenbeek R, Houtman R, de Wijn R, Boender P, Hilhorst R, Cohen Y, Onn A, Lax A, Yosepovich A, Litz S, Kalish S, Felemovicius R, Hout-Silony G, Gutman M, Shabtai M, Rosin D, Valeanu A, Winkler E, Sklair-Levy M, Kaufman B, Barshack I, Canu V, Sacconi A, Biagioni F, Mori F, di Benedetto A, Lorenzon L, di Agostino S, Cambria A, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro MG, Pescarmona E, Garofalo A, Blandino G, Ho T, Feng L, Lintula S, Orpana KA, Stenman J, El Messaoudi S, Mouliere F, del Rio M, Guedj AS, Gongora C, Molina FM, Lamy PJ, Lopez-Crapez E, Rolet F, Mathonnet M, Ychou M, Pezet D, Thierry AR, Manuarii M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Menetrier-Caux C. Technology & tools development. Ann Oncol 2012. [DOI: 10.1093/annonc/mds163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Lin N, Danso M, David A, Muscato J, Ellis C, DeSilvio M, Garofalo A, Nagarwala Y, Winer E. OT1-02-02: HALT MBC: HER2 Suppression with the Addition of Lapatinib to Trastuzumab in HER2−Positive Metastatic Breast Cancer (LPT112515). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot1-02-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Lapatinib in combination with trastuzumab enhanced anti-tumor activity in HER2−positive breast cancer (BC) preclinical models. In patients (pts) with trastuzumab-treated, HER2−positive metastatic (M) BC, treatment with the combination was associated with longer progression-free (PFS) and overall survival (OS) compared with lapatinib alone. In pts with stage II/III BC, preoperative treatment with the combination plus paclitaxel resulted in significantly higher pathological complete response rates compared with paclitaxel combined with either agent alone. This evidence supports the concept of dual HER2 blockade as a treatment strategy for HER2−positive BC. This present study is designed to evaluate whether the addition of lapatinib improves PFS among women with HER2−positive MBC receiving trastuzumab as maintenance therapy.
Trial Design In this open-label, Phase III study, pts are stratified by line of treatment (first/second) and hormone receptor status (positive/negative) then randomized 1:1 to receive maintenance treatment with either lapatinib (1000mg once daily, continuously) in combination with trastuzumab (6mg/kg once every 3 weeks [Q3W]) or trastuzumab (6mg/kg Q3W) alone. Pts will receive study treatment until disease progression, death, discontinuation due to adverse events or other reasons.
Eligibility Criteria Pts with HER2−positive MBC who have completed 12–24 weeks of first- or second-line treatment with trastuzumab plus chemotherapy and have objective response or stable disease. Pts with stable brain metastasis are eligible if entering the study on second-line treatment.
Specific Aims The primary objective is to compare PFS of lapatinib in combination with trastuzumab to trastuzumab as continued HER2 suppression therapy. Secondary objectives are to evaluate OS, clinical benefit rate, safety and tolerability.
Statistical Methods Efficacy endpoints will be analyzed in the intent to treat population. A total of 193 PFS events from 280 randomized pts will be required to detect a 50% increase in median PFS in pts who receive lapatinib plus trastuzumab compared with trastuzumab (median PFS time is 27 versus 18 weeks, respectively); hazard ratio of 0.67 with an 80% power and a 1-sided type I error of 0.025.
Present and Target Accrual Sixteen of the target 280 pts have been randomized. The trial is currently open for accrual in the United States and Canada.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT1-02-02.
Collapse
Affiliation(s)
- N Lin
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - M Danso
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - A David
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - J Muscato
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - C Ellis
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - M DeSilvio
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - A Garofalo
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - Y Nagarwala
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| | - E Winer
- 1Dana-Farber Cancer Institute; Virginia Oncology Associates; Augusta Oncology Associates; Missouri Cancer Associates; GlaxoSmithKline
| |
Collapse
|
31
|
Cavaliere F, De Simone M, Virzì S, Deraco M, Rossi CR, Garofalo A, Di Filippo F, Giannarelli D, Vaira M, Valle M, Pilati P, Perri P, La Pinta M, Monsellato I, Guadagni F. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 2010; 37:148-54. [PMID: 21093205 DOI: 10.1016/j.ejso.2010.10.014] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2010] [Accepted: 10/26/2010] [Indexed: 12/23/2022] Open
Abstract
AIM The present study was specifically designed to assess the major clinical and pathological variables of patients with colorectal peritoneal carcinomatosis in order to investigate whether currently used criteria appropriately select candidates for peritonectomy procedures (cytoreductive surgery) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). PATIENTS AND METHODS Preoperative, operative and follow-up data on 146 consecutive patients presenting with peritoneal carcinomatosis of colorectal origin and treated by surgical cytoreduction combined with HIPEC in 5 Italian Hospital and University Centers were prospectively entered in a common database. Univariate and multivariate analyses were used to assess the prognostic value of clinical and pathologic factors. RESULTS Over a minimum 24-month follow-up, the overall morbidity rate was 27.4% (mortality rate: 2.7%) and was directly related to the extent of surgery. Peritoneal cancer index (PCI), unfavorable peritoneal sites, synchronous or previously resected liver metastasis and the completeness of cytoreduction, all emerged as independent prognostic factors correlated with survival. CONCLUSIONS Until research provides more effective criteria for selecting patients based upon the biomolecular features of carcinomatosis, patients should be selected according to the existing independent prognostic variables.
Collapse
Affiliation(s)
- F Cavaliere
- Department of Surgery, San Giovanni Hospital, Via dell'Amba Aradam 9, 00184 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients. J Surg Oncol 2009; 100:331-4. [PMID: 19697441 DOI: 10.1002/jso.21321] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach. From September 2001 to August 2008, 52 patients were treated with this new modality. No treatment-related mortality was observed. Median survival was 98 days. One patient developed a clinical recurrence. Laparoscopic HIPEC is a safe and effective method for palliating malignant ascites.
Collapse
Affiliation(s)
- M Valle
- Department of Surgical Oncology, Digestive Branch, Regina Elena National Cancer Institute, Rome, Italy
| | | | | |
Collapse
|
33
|
Capone A, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol 2007. [PMID: 20213741 DOI: 10.1002/jso] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Peritoneal carcinomatosis is a common evolution of many abdominal and pelvic malignancies. Over the last decade novel therapeutic approaches have emerged combining cytoreductive surgery with perioperative intraperitoneal chemotherapy. Aim of our study was to assess frequency, sites, and organisms of postoperative infections in this surgery and to evaluate associated risk factors and clinical outcome. METHODS Retrospective study of postoperative infection in 30 patients undergoing combined cytoreductive surgery and hypertermic intraoperative chemotherapy in an oncologic surgery in Rome, between June 2001 and December 2004. RESULTS Twenty-nine postoperative infections were recorded in 11 patients (36.7%; 2.6 infections per patient), including 13 surgical site infections, 8 clinical sepsis, 6 bloodstream infections, and 2 pneumonias. At multivariate analysis, total peritonectomy was found as independent variable associated to postoperative infection. Mortality rates were 36.4% and 5% among patients with and without postoperative infections, respectively (P = 0.04). Four of the 5 patients with invasive candidosis died. CONCLUSIONS Peritonectomy procedures have an high risk of postoperative infections, prolonged hospital stay, and high morbidity and mortality. The increasing role of this surgery for the treatment of peritoneal carcinomatosis should strengthen the need for a careful evaluation of possible risk factors for postoperative infections, including the role of colonizing organisms.
Collapse
Affiliation(s)
- A Capone
- National Institute for Infectious Diseases L. Spallanzani, Via Portuense, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
34
|
Maccarone D, Parzanese I, Torlone N, Caniglia L, Garofalo A, Famulari A. The Registry of Brain Deaths in Quality Control Program: Evaluation of Potentiality of Each Hospital in Abruzzo and Molise Regions. Transplant Proc 2007; 39:1749-51. [PMID: 17692603 DOI: 10.1016/j.transproceed.2007.05.023] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Quality control procedures in donation and transplantation of organ and tissue, which were started in 2001, are aspects of the activity of Regional Centre for Transplantation. Over the years there has been a significant increase in the number of diagnosed brain deaths that is close to the figure reported in the international literature of 50/60 per million inhabitants (p.m.i). Misidentification of brain death is still the most important cause of loss of organs for transplantation; in fact in Italy, there are some regions that overcome this value, but there are other regions in which the number of brain death identified is still low. Abruzzo and Molise in 2003 achieved the highest registered brain deaths (61 p.m.i.); in 2004, 51; in 2005, 43; and the projection for 2006 is about around 50. For this study we collected data from five hospitals with a neurosurgical unit, which were representative of procurement activity in two regions, because they had identified the most brain deaths, 53/65 in 2005. The data were compared among hospitals and with the Spanish country data (1999-2003), which was avant-garde for the processing of organ donation and transplantation in Europe. Some useful indices to define the theoretical capacity of donation for each hospital (ability to identify brain death, the cause of donor loss) were evaluated for determining the efficacy of the procedure in organ procurement.
Collapse
Affiliation(s)
- D Maccarone
- Centro Regionale per i Trapianti Regione Abruzzo, Regione Molise, L'Aquila, Italy.
| | | | | | | | | | | |
Collapse
|
35
|
Capone A, Valle M, Proietti F, Federici O, Garofalo A, Petrosillo N. Postoperative Infections in Cytoreductive Surgery With Hyperthermic Intraperitoneal Intraoperative Chemotherapy for Peritoneal Carcinomatosis. J Surg Oncol 2007; 96:507-13. [PMID: 17708508 DOI: 10.1002/jso.20837] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Peritoneal carcinomatosis is a common evolution of many abdominal and pelvic malignancies. Over the last decade novel therapeutic approaches have emerged combining cytoreductive surgery with perioperative intraperitoneal chemotherapy. Aim of our study was to assess frequency, sites, and organisms of postoperative infections in this surgery and to evaluate associated risk factors and clinical outcome. METHODS Retrospective study of postoperative infection in 30 patients undergoing combined cytoreductive surgery and hypertermic intraoperative chemotherapy in an oncologic surgery in Rome, between June 2001 and December 2004. RESULTS Twenty-nine postoperative infections were recorded in 11 patients (36.7%; 2.6 infections per patient), including 13 surgical site infections, 8 clinical sepsis, 6 bloodstream infections, and 2 pneumonias. At multivariate analysis, total peritonectomy was found as independent variable associated to postoperative infection. Mortality rates were 36.4% and 5% among patients with and without postoperative infections, respectively (P = 0.04). Four of the 5 patients with invasive candidosis died. CONCLUSIONS Peritonectomy procedures have an high risk of postoperative infections, prolonged hospital stay, and high morbidity and mortality. The increasing role of this surgery for the treatment of peritoneal carcinomatosis should strengthen the need for a careful evaluation of possible risk factors for postoperative infections, including the role of colonizing organisms.
Collapse
Affiliation(s)
- A Capone
- National Institute for Infectious Diseases L. Spallanzani, Via Portuense, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
36
|
Cavaliere F, Valle M, De Simone M, Deraco M, Rossi CR, Di Filippo F, Verzi S, Giannarelli D, Perri P, Pilati PL, Vaira M, Di Filippo S, Garofalo A. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. In Vivo 2006; 20:747-50. [PMID: 17203760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
A multicentric study has been carried out on 120 patients affected by peritoneal carcinomatosis from colorectal cancer. Patients have been treated by cytoreductive surgery and intra-operative hyperthermic chemoperfusion (HIPEC) with cisplatin (CDDP) and mitomycin-c (MMC). A small group of patients were treated with oxaliplatin (LOHP) following the Elias et al. scheme [intravenous 5-fluorouracil (400 mg/m2) and leucovorin (20 mg/m2) followed by intraperitoneal perfusion with LOHP (460 mg/m2) in 2 l/m2, during 30 min at 43 degrees C]. CC-0 cytoreduction was achieved in 85.2% of the patients. Major morbidity and mortality was 22.5% and 3.3%, respectively. No G4 toxicity was registered. The three-year survival was 25.8%. The difference in survival evaluating complete cytoreduction (CC-0) vs. incomplete (CC1-2; residual tumor nodules greater than 2.5 mm) was statistically significant (p < 0.0001). Evaluating only the patients that could be cytoreduced to CC-0, the 3-year survival was raised to 33.5%. In our experience the peritoneal cancer index (PCI) has been demonstrated to be a weak prognostic factor reaching a statistical significance only after the exclusion of patients with resected hepatic metastases. The patients treated with oxaliplatin were alive and free-of-disease after a 16-month median follow-up.
Collapse
Affiliation(s)
- F Cavaliere
- Surgical Oncology, San Camillo-Forlanini Hospital, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2006. [PMID: 17072675 DOI: 10.1245/s10434-007-9599-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
38
|
Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, Hanna N, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2006; 14:128-33. [PMID: 17072675 DOI: 10.1245/s10434-006-9185-7] [Citation(s) in RCA: 294] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2006] [Revised: 06/02/2006] [Accepted: 06/02/2006] [Indexed: 12/11/2022]
|
39
|
Aiello F, Brizzi A, De Grazia O, Garofalo A, Grande F, Sinicropi MS, Dayam R, Neamati N. An approach to the stereo-controlled synthesis of polycyclic derivatives of l-4-thiazolidinecarboxylic acid active against HIV-1 integrase. Eur J Med Chem 2006; 41:914-7. [PMID: 16781021 DOI: 10.1016/j.ejmech.2006.03.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2005] [Revised: 03/10/2006] [Accepted: 03/20/2006] [Indexed: 10/24/2022]
Abstract
Herein, we describe a new strategy for the preparation of thiazolothiazepine-based inhibitors of human immunodeficiency virus type-1 integrase (IN). The present method allows facile preparation of the title compounds in a single enantiomeric form starting from l-4-thiazolidinecarboxylic acid. This method could be easily extended to the synthesis of several analogs derived from optically active cyclic aminoacids. We also present a putative model showing the interaction between l- and d-isomers of compound 1 in the IN active site. A sensibly lower IC(50) value was found for (-)-1 over racemic-1 in an anti-IN assay.
Collapse
Affiliation(s)
- F Aiello
- Dipartimento di Scienze Farmaceutiche, Università della Calabria, 87036 Arcavacata di Rende (Cs), Italy
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Lopez M, Comandone A, Adamo V, Apice G, Bearzi I, Bracci R, Carlini M, Carpano S, Condorelli S, Covello R, Cucchiara G, Di Filippo F, Doglietto GB, Ficorella C, Garofalo A, Gebbia N, Giuliani F, Massidda B, Messerini L, Palmirotta R, Tonelli F, Vidiri A. [Clinical guidelines for the management of gastrointestinal stromal tumors]. Clin Ter 2006; 157:283-99. [PMID: 16900856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Treatment of gastrointestinal stromal tumors (GIST) has been revolutioned by the recently discovered molecular mechanism responsible for the oncogenesis of this disease. In addition, due to the rapid progress at molecular and clinical level observed in the last few years, there is a need to review the current state of the art in order to delineate appropriate guidelines for the optimal management of these tumors. A panel of experts from several specialities, including medical oncology, surgery, pathology, molecular biology and imaging, were invited to participate in a meeting to present and discuss a number of pre-selected questions, and to achieve a consensus according to the categories of the National Comprehensive Cancer Network (NCCN) and the Standard Options Recommandations (SOR) of the French Federation of Cancer Centers. Generally, consensus points were from categories 2A of the NCCN and B2 of the SOR. Conventional histologic examination with immunohistochemistry for CD117, CD34, SMA, S-100 and desmin is considered standard. Molecular analysis for the identification of KIT and PDGFRA mutation may be indicated in CD117-negative GIST. Complete tumor resection with negative margins is the optimal surgical treatment. Adjuvant imatinib should be considered an experimental approach. Neoadjuvant imatinib is also experimental, although its use may be justified in unresectable or marginally resectable GIST. Imatinib should be started in metastatic or recurrent disease, and should be continued until progressive disease or drug intolerance. In these cases, sunitinib can be used. The optimal criteria for the assessment and monitoring of GIST undergoing imatinib therapy are not well known, but they should include reduction in tumor size and disease stabilization, as well as reduction of tumor density on CT scan and metabolic activity on PET scan.
Collapse
Affiliation(s)
- M Lopez
- Istituto Nazionale Tumori "Regina Elena", Via Elio Chianesi, 53 - 00144 Roma, Italia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Garofalo A, Valle M, Garcia J, Sugarbaker PH. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 2006; 32:682-5. [PMID: 16631341 DOI: 10.1016/j.ejso.2006.03.014] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2005] [Accepted: 03/02/2006] [Indexed: 02/06/2023] Open
Abstract
AIM To report the use of laparoscopic Intraperitoneal Hyperthermic Chemotherapy (LIPHC) in the treatment of malignant ascites. METHODS From September 2001 to December 2003, 14 patients between the age of 56 and 78years were treated. Ascites was from gastric cancer (5 cases), colorectal cancer (3 cases), ovarian cancer (3 cases), breast cancer (2 cases) and peritoneal mesothelioma (1 case). The LIPHC was carried out at 42 degrees C for 90 min with 1.5% dextrose solution as a carrier. Chemotherapy was cisplatin and doxorubicin or mitomycin depending on the type of primary tumor. The drains were left in situ after surgery and removed when perfuse drainage ceased. RESULTS Ascites was controlled in all the treated cases. A CT scan performed in follow-up showed a small, clinically undetectable, fluid accumulation in the pelvis of one patient. CONCLUSIONS This method resulted in benefit for those peritoneal carcinomatosis patients with debilitating malignant ascites who were excluded from cytoreductive surgery. Proficiency in laparoscopic staging procedures and experience in the management of carcinomatosis and intraperitoneal hyperthermic chemotherapy (IPHC) are required for the success of the procedure.
Collapse
Affiliation(s)
- A Garofalo
- General-Oncological Surgery, Department of Surgery, S. Camillo Hospital, Rome, Italy
| | | | | | | |
Collapse
|
42
|
Cargnello G, Pezza L, Gallo G, Camatta T, Coccato S, Pascarella G, Di Gaetano R, Casadei G, La Torre A, Spera G, Scaglione M, Moretti S, Garofalo A. D.M.R. ("Double Reasoned Maturing"): innovative technique of agronomic ecologic control of grey mould on grapevine. trials and various considerations. Commun Agric Appl Biol Sci 2006; 71:1055-61. [PMID: 17390859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
A study was carried out in order to identify agronomic ecologic solutions in the indirect grey mould control on grapevine. These specific trials started since 1990 and, after years of validation, now they are applied by the entrepreneur to the business practice in the different pedological and climatic area and on different cultivars and forms of growing. The technique of "Doppia Maturazione Ragionata" (D.M.R.) ("Doubles Reasoned Maturing") consists of far "completing" the maturing of the grape for wilting on the plant through the reasoned cut of the heads to fruit e/o of shoots. The application of D.M.R., besides determining valid and important technical and qualitative (organoleptic, economic and social quality) improvements on the product, is particularly effective in the indirect grey mould control on grapevine. Such technique, in fact, allows us to vintage the grape during the business demands and not when imposed by Botrytis cinerea; it has been possible, in some cases, to vintage in December and over, without problems of B. cinerea. The trials have shown the technical, economic, social sustainability of D.M.R. application. This paper reports all trials that have brought, by now from years, to apply in the practice DMR (Double Reasoned Maturing).
Collapse
Affiliation(s)
- G Cargnello
- C.R.A. - Viticultural Research Institute, S.O.C. Tecniche Colturali, Viale XXVIII Aprile 26, IT-31015 Conegliano (TV), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Federici O, Valle M, Moles N, De Rosa B, Garofalo A. [Jaundice from neoplastic lymphangitis in patients undergoing D2/3 lymphadenectomy for gastric neoplasms. Our experience]. Suppl Tumori 2005; 4:S73. [PMID: 16437912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
The surgical treatment of gastric adenocarcinoma foresees, toghether with the gastric resection, the lymph nodes resection as indicated by the Japanese Research Society for Gastric Cancer. Obstructive jaundice, as a consequence of lymph nodes metastases, is one of the most debilitating pattern of recurrence. In the present paper three cases of jaundice, observed during the follow-up, after D2-D3 gastric adenocarcinoma resection, with no evidence of lymph nodes recurrence either at the restaging or at the intraoperative esploration are reported. We believe that the jaundice etiology, in the present series, could be due to neoplastic lymphangites of the biliar wall.
Collapse
Affiliation(s)
- O Federici
- Azienda Ospedaliera San Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
| | | | | | | | | |
Collapse
|
44
|
De Rosa B, Valle M, Cavaliere F, Federici O, Sperduti I, Garofalo A. [Integrated treatment of peritoneal carcinomatosis: preliminary experience]. Suppl Tumori 2005; 4:S117-8. [PMID: 16437942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
A prospective study has been carried on 37 patients, 35 of them affected by peritoneal carcinomatosis from ovarian (16), appendiceal (7), colorectal (5), mesothelial (4), gastric (3) primary and 2 affected by sarcomatosis. Mean PCI was 22 (median, 22). Eighty-five percent of the patients presented debilitating ascites associated in 23% to initial symptoms of intestinal obstruction. All the patients have been treated with peritonectomy and intraoperative hyperthermic chemoperfusion and CC 0-1 cytoreduction was achieved in 81%. Major morbidity and mortality was respectively 37.8% and 16.2%, where 5 out 6 deaths recorded in the first 19 months of our experience, representing our learning curve. At a median follow-up of 8 months (range, 1-54), 18 patients are alive and disease-free and 4 patients are alive with disease. Two-yr overall survival was 49.1% for all series. Difference in survival evaluating CC 0-1 vs CC 2 patients was statistically significant.
Collapse
Affiliation(s)
- B De Rosa
- Azienda Ospedaliera San Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
| | | | | | | | | | | |
Collapse
|
45
|
Leone A, Pisa R, Gasbarra R, Graziano P, Remotti D, Valle M, Garofalo A. [Association of mutations of K-RAS oncogene and deletions of 18Q with lymph node metastasis of colorectal cancer]. Suppl Tumori 2005; 4:S207. [PMID: 16437991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Molecular characterization of gastrointestinal cancer has greatly helped the definition of the key steps of the malignant transformation process and made it the best understood among the malignant cancers. Genetic influences on prognosis may have important implications for the management of the disease and help to design patient-tailored therapy. In order to acquire additional knowledge on this issue we have commenced an institutional study with the aim to identify the most frequent molecular alterations and make a correlation with the conventional histopathological parameters.
Collapse
Affiliation(s)
- A Leone
- Anatomia Patologica e Chirurgia Generale Oncologica, AO San Camillo Forlanini, Roma
| | | | | | | | | | | | | |
Collapse
|
46
|
Corona F, Valle M, Federici O, De Rosa B, Garofalo A. [Modified surgical technique of pancreas-preserving lymphadenectomy]. Suppl Tumori 2005; 4:S83. [PMID: 16437919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Affiliation(s)
- F Corona
- Azienda Ospedaliera San Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
| | | | | | | | | |
Collapse
|
47
|
Leone A, Pisa R, Gasbarra R, Costanzi-Porrini S, Cavazzana A, Bevilacqua G, Graziano P, Remotti D, Valle M, Garofalo A. [Assessment of the presence of mutations of the epidermal growth factor receptors in tumors of various histologies]. Suppl Tumori 2005; 4:S203. [PMID: 16437988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Recent reports from US and Japan have established that mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (Egfr) occur in a subset of patients with lung cancer that respond to therapy with gefitinib, a TK inhibitor. To gain further insights into the role of Egfr in carcinogenesis of lung and tumors of diverse histology, that are currently under investigation with drugs of the same class, we have taken in examination a panel of tumors consisting in 110 pulmonary adenocarcinomas, 40 pulmonary squamous carcinomas, 40 gastric adenocarcinomas and 40 colorectal adenocarcinomas. The sequence analysis of exon 19 and 21 of the Egfr has allowed the identification of 10 cases exhibiting specific deletions in exon 19 and 1 case with point mutation in a conserved residue in exon 21. All Egfr mutations occur specifically in lung adenocarcinomas while tumors of different histology result unaffected. The rate of mutation affecting these other tumors is either very rare, involves different domains of the receptor or other tyrosine kinases. The molecular analysis of the Egfr gene can help identify patients that will benefit from gefitinib therapy.
Collapse
Affiliation(s)
- A Leone
- Anatomia Patologica e Chirurgia Generale Oncologica, AO San Camillo Forlanini, Roma
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Valle M, Garofalo A, Federici O, Cavaliere F. [Laparoscopic intraperitoneal antiblastic hyperthermic chemoperfusion in the treatment of refractory neoplastic ascites. Preliminary results]. Suppl Tumori 2005; 4:S122-3. [PMID: 16437944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
A method of laparoscopic continuous hyperthermic peritoneal perfusion (CHPP) is proposed for the treatment of debilitating malignant ascites. The authors report 14 cases of peritoneal malignancy, not amenable to peritonectomy due to massive infiltration of the small bowel. The ascites disappeared in all treated cases.
Collapse
Affiliation(s)
- M Valle
- Azienda Ospedaliera S. Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
| | | | | | | |
Collapse
|
49
|
Cavaliere F, Valle M, De Rosa B, Federici O, Giannarelli D, Garofalo A. [Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve]. Suppl Tumori 2005; 4:S119-21. [PMID: 16437943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
A prospective study has been carried on 37 patients affected by peritoneal carcinomatosis from various primary. Patients have been treated by cytoreductive surgery and intraoperative hyperthermic chemoperfusion. CC 0-1 has been achieved in 81%. The temperature distribution study showed a "barrier effect" with no statistically significant correlation to the survival. Major morbidity and mortality was respectively 37.8% and 16.2%. Two-yr overall survival was 49.1% for all series. Morbidity was significantly directly correlated to the duration of the surgical treatment. A learning curve of 19 months have been observed, after that only one death out 21 procedures has been recorded. Peritoneal carcinomatosis patients, that are submitted to integrated treatment, need a peculiar management that is not comparable to any other in the oncological setting and that requires specific competence.
Collapse
Affiliation(s)
- F Cavaliere
- Azienda Ospedaliera San Camillo Forlanini, UOC di Chirurgia Generale Oncologica, Roma
| | | | | | | | | | | |
Collapse
|
50
|
Valle M, Federici O, Moles N, De Rosa B, Garofalo A. [Remission of intraoperative complications in videolaparoscopic surgery of the colorectum]. Suppl Tumori 2005; 4:S132. [PMID: 16437950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Intraoperative morbidity in the laparoscopic approach for colorectal surgery is 5.6%. We tried our experience in 4 out of 70 laparoscopic procedures. In 3 cases it was dealt with one missed estate of the suture of the rectal stump. Two of them were treated with new resection of the rectal stump using in one case the opening of the anastomosis. In 1 case of bleeding of a sacral vessel we practiced a service 6 cm Pfannestiel incision of 6 cm to handle the hemorrhage. Intraoperative morbidity has not modified the course of the postoperative one.
Collapse
Affiliation(s)
- M Valle
- UOC di Chirurgia Generale Oncologica, Azienda Ospedaliera San Camillo Forlanini, Roma
| | | | | | | | | |
Collapse
|